NCT00096200View on ClinicalTrials.gov

Sorafenib With or Without Paclitaxel and Carboplatin in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

August 31, 2004

Primary Completion Date

April 21, 2011

Study Completion Date

August 31, 2011

Conditions
Recurrent Fallopian Tube CarcinomaRecurrent Ovarian CarcinomaRecurrent Primary Peritoneal Carcinoma
Interventions
DRUG

Carboplatin

Given IV

DRUG

Paclitaxel

Given IV

DRUG

Sorafenib Tosylate

Given orally

Trial Locations (5)

23298

Virginia Commonwealth University/Massey Cancer Center, Richmond

33612

Moffitt Cancer Center at Tampa General Hospital, Tampa

Moffitt Cancer Center, Tampa

44060

Lake University Ireland Cancer Center, Mentor

44106

Case Western Reserve University, Cleveland

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00096200 - Sorafenib With or Without Paclitaxel and Carboplatin in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer | Biotech Hunter | Biotech Hunter